Trials / Completed
CompletedNCT03285802
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Greater Baltimore Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label treatment program following basic prescribing information for patients with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and limited treatment alternatives.
Detailed description
The objective is to provide access to everolimus for patients with Recurrent UPSC and limited treatment alternatives. Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Letrozole | Letrozole 2.5mg will be taken daily q 30 days |
| DRUG | Everolimus | Everolimus 10mg daily q 28 days |
Timeline
- Start date
- 2017-09-07
- Primary completion
- 2019-02-12
- Completion
- 2019-02-12
- First posted
- 2017-09-18
- Last updated
- 2020-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03285802. Inclusion in this directory is not an endorsement.